Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:15 August 2023

M18-868: This phase III study is evaluating whether targeted therapy (telisotuzumab vedotin) is more effective than chemotherapy (docetaxel) in people with non-small cell lung cancerA Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

Eligible participants will be randomly allocated to either the Experimental Arm or the Active Comparator Arm. In the Experimental Arm, participants will receive telisotuzumab vedotin every 2 weeks via intravenous (IV) infusion. In the Active Comparator Arm, participants will receive docetaxel every 3 weeks via IV infusion.

Age

People 18+

Phase

III

Trial Acronym

M18-868

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT04928846
M18-868

Commercial Sponsor

AbbVie

Scientific Title

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have been diagnosed with a prior or secondary type of cancer.
You have had certain treatments, surgical procedures or drugs.

Exclusion

You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Your cancer has not spread to other parts of the body.
Your cancer has spread to other parts of the body.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy